The Complement 3 Glomerulopathy Market is Expected to Gain Momentum during the Study Period 2017-30 With a CAGR of 30%, estimates DelveInsight

The Complement 3 Glomerulopathy (C3G) Market is set to grow substantially owing to the current treatment practices (mainly off-label treatments), launch of pipeline therapies, increase in funding, better awareness programmes and advent of novel biomarkers for better diagnosis.

LAS VEGAS, Jan. 13, 2021 /PRNewswire/ -- DelveInsight's 'Complement 3 Glomerulopathy Market Report 2030' report delivers an in-depth understanding of the Complement 3 Glomerulopathy, historical and forecasted C3G epidemiology, and current treatment practices. The report proffers a detailed coverage of the Complement 3 Glomerulopathy market drivers, market barriers and unmet medical needs that are expected to shape the C3G market outlook in the next decade in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the highlights of the Complement 3 Glomerulopathy Market report: 

• The present Complement 3 Glomerulopathy market has no approved therapy. The treatment market is dominated by off-label prescription drugs such Immunosuppressant, Steroids, Renin–angiotensin–aldosterone system Inhibitors (RAAS), and other supportive therapies (also including Antibody regimens: Eculizumab and Rituximab).
• The growth of the C3G market size is driven by a few potential emerging players, which are investigating their product candidates in the phase II clinical developmental stage, namely, Alexion Pharmaceuticals (Danicopan), Omeros Corporation (Narsoplimab), Apellis Pharmaceuticals (Pegcetacoplan), and Novartis Pharmaceuticals (LNP023 (TBD)).
• The current C3G market possesses no emerging therapies in their phase III developmental stage.
• The expected launch of C3G pipeline therapies, Danicopan (Alexion Pharmaceuticals), Narsoplimab (Omeros Corporation), Pegcetacoplan (Apellis Pharmaceuticals) and LNP023 (Novartis Pharmaceuticals), shall accelerate the growth of the C3G market size in the coming years.

For more insights into the market landscape, visit Complement 3 Glomerulopathy therapeutic landscape

Complement 3 Glomerulopathy (C3G) is a rare, chronic renal disease that hinders the normal filtering mechanism of the kidneys attributable to excess accumulation of C3G proteins. The total diagnosed C3G prevalence in the 7MM (the US, EU5 (the UK, Italy, Germany, Spain, and France) and Japan) in 2020 is estimated to be approximately 8,456. Years of research have demonstrated that the condition can have two identifiable types, namely Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN). However, as per the C3G epidemiological analysis, C3GN is more prevalent than DDD. Furthermore, 6,032 cases of C3GN and 2,424 cases of DDD were reported to be found in the 7MM. 

The Complement 3 Glomerulopathy Market Report provides historical as well as forecasted epidemiological analysis segmented into: 

• Total Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G), 
• Type-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G) 
• Age-specific Diagnosed Prevalent Population of Complement 3 Glomerulopathy (C3G) 

Request for sample for more insights @ Complement 3 Glomerulopathy Market 

Complement 3 glomerulopathy Therapeutic Market

The present Complement 3 Glomerulopathy market is majorly dominated by off-label prescription drugs. The therapeutic market majorly consists of immunosuppressants, steroids, renin-angiotensin-aldosterone system inhibitors (RAAS), and other supportive therapies, including antibody regimens such as Eculizumab and Rituximab. Furthermore, C3G patients undergo reno-protective measures, including lifestyle advice, an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker to control hypertension and proteinuria, and lipid-lowering treatment. These medications can improve the protective effect of immunosuppressive medication. Plasma therapy offered seemed to have a mixed response as it may be beneficial in C3G patients who have AKI but not in patients with C3 nephritic factors. 

Current Therapies 

• Immunosuppressants 
• Steroids
• Renin-angiotensin-aldosterone system Inhibitors (RAAS)
• Other Supportive Therapies (also including Antibody regimens: Eculizumab and Rituximab)

The C3G therapy market has major unmet needs owing to a serious lack of C3G-specific medications. Almost half of the C3G patients undergo kidney transplantation. Even after kidney transplantation, in around 67–90% and clinically in 50–60% of patients, C3G relapsed. Although clinical trials are underway to find an efficient and potential curative option, the enrolment in the clinical studies owing to the rarity of the disease poses another hurdle. 

The emerging C3G market possesses an intermediate pipeline with key pharma companies developing several therapies in different stages of development including Alexion Pharmaceuticals, Omeros Corporation, Apellis Pharmaceuticals, Avacopan, Novartis, Amyndas Pharmaceuticals, Visterra among others. 

The present Complement 3 Glomerulopathy drug market has no approved therapy, therefore, the upcoming therapies in the market expected to get launched in the next decade shall fuel the market size growth and bring more opportunities for the key pharmaceutical companies investigating their molecules for C3G. Several organizations such as WeC3G, National Kidney Foundation (NKF), American Society of Nephrology (ASN), Kidney Disease: International Global Organization (KDIGO), Japanese Society of Nephrology (JSN), among others are working vigorously to make people better aware of the condition, its therapeutic options and diagnosis. Since, the clinical presentation of ICGN and PIGN is more or less similar to that of C3G, there are often chances of differential diagnosis leading to delay in right treatment option. Therefore, there is a requirement for better diagnostics modalities in the Complement 3 Glomerulopathy Market. However, the advent of novel biomarkers in the coming future is anticipated to overcome this challenge.

Know more about the report offerings @ C3G Therapeutics Market 

Complement 3 Glomerulopathy Pipeline Therapies 

• Danicopan (Alexion Pharmaceuticals)
• Narsoplimab (Omeros Corporation)
• Pegcetacoplan (Apellis Pharmaceuticals) 
• ChemoCentryx (Avacopan) 
• LNP023 (Novartis Pharmaceuticals) 

Scope of the Report

• Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
• Markets Segmentation: By Geographies and By Therapies (Historical and Forecasted, Current and Upcoming)
• Companies Covered: Alexion Pharmaceuticals, Omeros Corporation, Apellis Pharmaceuticals, Avacopan, Novartis, Amyndas Pharmaceuticals, Visterra among others.
• Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis.
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report @ Complement 3 Glomerulopathy Market Landscape 

Table of Contents 

Related Reports 

Complement 3 Glomerulopathy Epidemiology Forecast

DelveInsight's 'Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast – 2030' report delivers an in-depth understanding of the disease, historical and forecasted Complement 3 Glomerulopathy (C3G) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Complement 3 Glomerulopathy Pipeline 

"Complement 3 Glomerulopathy Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Complement 3 Glomerulopathy market.

Acute Renal Failure Acute Kidney Injury Market

DelveInsight's "Acute Renal Failure (ARF) (Acute Kidney Injury) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute Renal Failure (ARF) (Acute Kidney Injury), historical and forecasted epidemiology as well as the Acute Renal Failure (ARF) (Acute Kidney Injury) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Advanced Renal Cell Carcinoma Market

DelveInsight's "Advanced Renal Cell Carcinoma (RCC) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Renal Cell Carcinoma (RCC), historical and forecasted epidemiology as well as the Advanced Renal Cell Carcinoma (RCC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chronic Renal Kidney Transplant Rejection Market

DelveInsight's "Chronic Renal/Kidney Transplant Rejection - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Renal/Kidney Transplant Rejection, historical and forecasted epidemiology as well as the Chronic Renal/Kidney Transplant Rejection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Chronic Kidney Disease Chronic Renal Failure Market

DelveInsight's ''Chronic kidney disease (CKD) - Market Insights, Epidemiology and Market Forecast-2030" report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of CKD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Distal Renal Tubular Acidosis Market

DelveInsight's "Distal Renal Tubular Acidosis (dRTA) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Distal Renal Tubular Acidosis (dRTA), historical and forecasted epidemiology as well as the Distal Renal Tubular Acidosis (dRTA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

End Stage Renal Disease Market

DelveInsight's "End-Stage Renal Disease (ESRD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the End-Stage Renal Disease (ESRD), historical and forecasted epidemiology as well as the End-Stage Renal Disease (ESRD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Metastatic Renal Cell Carcinoma Market

DelveInsight's "Metastatic Renal Cell Carcinoma (mRCC) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Metastatic Renal Cell Carcinoma (mRCC), historical and forecasted epidemiology as well as the Metastatic Renal Cell Carcinoma (mRCC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Catheter Related Bloodstream Infection Market

DelveInsight's 'Catheter-Related Bloodstream Infection (CRBSI) -Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the catheter-related bloodstream infection, historical and forecasted epidemiology as well as the catheter-related bloodstream infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us:

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg